Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M ‘gatekeeper’ mutant cells and not active to wild-type EGFR NSCLC cells. Ib...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Wu, Hong, Wang, Aoli, Zhang, Wei, Wang, Beilei, Chen, Cheng, Wang, Wenchao, Hu, Chen, Ye, Zi, Zhao, Zheng, Wang, Li, Li, Xixiang, Yu, Kailin, Liu, Juan, Wu, Jiaxin, Yan, Xiao-E, Zhao, Peng, Wang, Jinhua, Wang, Chu, Weisberg, Ellen L., Gray, Nathanael S., Yun, Cai-Hong, Liu, Jing, Chen, Liang, Liu, Qingsong
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2015
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741607/
https://ncbi.nlm.nih.gov/pubmed/26375053
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares